Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation & Amortization (2017 - 2026)

Crinetics Pharmaceuticals has reported Accumulated Depreciation & Amortization for 10 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation & Amortization rose 5.19% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (up 5.19% YoY), and the FY2025 full-year result was $3.9 million, up 39.29% from the prior year.
• Accumulated Depreciation & Amortization for Q1 2026 stood at $9.1 million, up from $3.9 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $9.6 million in Q2 2025, with the low at $1.1 million in Q4 2023.
• Average Accumulated Depreciation & Amortization over 5 years is $5.3 million, with a median of $4.6 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization tumbled 73.07% in 2023 and surged 154.55% in 2024.
• Tracing CRNX's Accumulated Depreciation & Amortization over 5 years: stood at $4.1 million in 2022, then plunged by 73.07% to $1.1 million in 2023, then surged by 154.55% to $2.8 million in 2024, then jumped by 39.29% to $3.9 million in 2025, then surged by 133.03% to $9.1 million in 2026.
• The last three Accumulated Depreciation & Amortization figures came in at $9.1 million (Q1 2026), $3.9 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.

Peer Comparison